|
⚲
|
| Pervasis Therapeutics Inc | |
|---|---|
| Firm | |
| Fund # | |
| CIK # | 0001309869 |
| Sale | 2009-08-31 ($17.4 M Offered, $10.0 M Sold) |
| Fund | |
| Phone | 6176213407 |
| Address | One Kendall Square, Suite B6101 Cambridge, 02139-1663 |
| Source | [EDGAR] |
| Fund AUM and Sold ($M) |
|---|
| Fund Details | |
|---|---|
| Director | |
| Custodian | |
| Auditor | |
| Marketer | |
| Broker | |
| Jurisdiction |
| Directors | 2011 - 2025 |
|---|---|
| Amir Nashat | |
| Frederic Chereau | |
| Elazer Edelman | |
| Robert Higgins | |
| Robert Langer | |
| Earl Collier | |
| Edwin Kania | |
| Yoram Richter | |
| Peter Hutt | |
| Helen Nugent | |
| Frank Litvack |
| Comparable Firms | State | AUM ($B) |
|---|---|---|
|
eWRLD Corp.
✚
|
0.0 | |
|
EX-0604 Fund I, a series of HyperGuap, LP
✚
|
0.0 | |
|
EX-0926 Fund I, a series of HENRY Collective Ventures, LP
✚
|
0.0 | |
|
Exa Biosciences, Inc.
✚
|
0.0 | |
|
Examen, Inc. /DE
✚
|
0.0 | |
|
Excela Capital US Fund LP
✚
|
0.0 | |
|
ExcelFin Acquisition Corp.
✚
|
0.0 | |
|
Exchange Place: All Cap II LP
✚
|
0.0 | |
|
ExchangeRight Fee Participation LLC
✚
|
0.0 | |
|
EVP Sama Investor LLC
✚
|
0.0 |